Literature DB >> 17048869

Hydrazone- and hydrazide-containing N-substituted glycines as peptoid surrogates for expedited library synthesis: application to the preparation of Tsg101-directed HIV-1 budding antagonists.

Fa Liu1, Andrew G Stephen, Catherine S Adamson, Karine Gousset, M Javad Aman, Eric O Freed, Robert J Fisher, Terrence R Burke.   

Abstract

Replacing the Pro6 in the p6(Gag)-derived 9-mer "P-E-P-T-A-P-P-E-E" with N-substituted glycine (NSG) residues is problematic. However, incorporation of hydrazone amides ("peptoid hydrazones") can be readily achieved in library fashion. Furthermore, reduction of these hydrazones to N-substituted "peptoid hydrazides" affords a facile route to library diversification. This approach is demonstrated by application to Tsg101-binding compounds designed as potential HIV budding antagonists. [reaction: see text]

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17048869      PMCID: PMC2547129          DOI: 10.1021/ol0622211

Source DB:  PubMed          Journal:  Org Lett        ISSN: 1523-7052            Impact factor:   6.005


  15 in total

1.  Solution-phase synthesis of aminooxy peptoids in the C to N and N to C directions.

Authors:  Injae Shin; Kisoo Park
Journal:  Org Lett       Date:  2002-03-21       Impact factor: 6.005

Review 2.  Mimicry of bioactive peptides via non-natural, sequence-specific peptidomimetic oligomers.

Authors:  James A Patch; Annelise E Barron
Journal:  Curr Opin Chem Biol       Date:  2002-12       Impact factor: 8.822

3.  Design and pharmacology of peptoids and peptide-peptoid hybrids based on the melanocortin agonists core tetrapeptide sequence.

Authors:  Jerry Ryan Holder; Rayna M Bauzo; Zhimin Xiang; Joseph Scott; Carrie Haskell-Luevano
Journal:  Bioorg Med Chem Lett       Date:  2003-12-15       Impact factor: 2.823

4.  C-terminus of a long alpha-neurotoxin is highly mobile when bound to the nicotinic acetylcholine receptor: a time-resolved fluorescence anisotropy approach.

Authors:  David A Johnson
Journal:  Biophys Chem       Date:  2005-08-01       Impact factor: 2.352

5.  Improving SH3 domain ligand selectivity using a non-natural scaffold.

Authors:  J T Nguyen; M Porter; M Amoui; W T Miller; R N Zuckermann; W A Lim
Journal:  Chem Biol       Date:  2000-07

6.  Retro hydrazino-azapeptoids as peptidomimetics of proteasome inhibitors.

Authors:  Sandrine Aubin; Bénédicte Martin; Jean-Guy Delcros; Yannick Arlot-Bonnemains; Michèle Baudy-Floc'h
Journal:  J Med Chem       Date:  2005-01-13       Impact factor: 7.446

7.  Solid Phase Synthesis of beta-Peptoids: N-Substituted beta-Aminopropionic Acid Oligomers.

Authors:  Bruce C. Hamper; Stephen A. Kolodziej; Angela M. Scates; Ronald G. Smith; Enriqueta Cortez
Journal:  J Org Chem       Date:  1998-02-06       Impact factor: 4.354

8.  Interaction of N-terminal fragments of fibronectin with synthetic and recombinant D motifs from its binding protein on Staphylococcus aureus studied using fluorescence anisotropy.

Authors:  S Huff; Y V Matsuka; M J McGavin; K C Ingham
Journal:  J Biol Chem       Date:  1994-06-03       Impact factor: 5.157

9.  Peptoids: a modular approach to drug discovery.

Authors:  R J Simon; R S Kania; R N Zuckermann; V D Huebner; D A Jewell; S Banville; S Ng; L Wang; S Rosenberg; C K Marlowe
Journal:  Proc Natl Acad Sci U S A       Date:  1992-10-15       Impact factor: 11.205

10.  Exploiting the basis of proline recognition by SH3 and WW domains: design of N-substituted inhibitors.

Authors:  J T Nguyen; C W Turck; F E Cohen; R N Zuckermann; W A Lim
Journal:  Science       Date:  1998-12-11       Impact factor: 47.728

View more
  22 in total

1.  Synthesis of a Homologous Series of Side Chain Extended Orthogonally-Protected Aminooxy-Containing Amino Acids.

Authors:  Fa Liu; Joshua Thomas; Terrence R Burke
Journal:  Synthesis (Stuttg)       Date:  2008       Impact factor: 3.157

Review 2.  Novel approaches to inhibiting HIV-1 replication.

Authors:  Catherine S Adamson; Eric O Freed
Journal:  Antiviral Res       Date:  2009-09-24       Impact factor: 5.970

Review 3.  HIV type 1 Gag as a target for antiviral therapy.

Authors:  Abdul A Waheed; Eric O Freed
Journal:  AIDS Res Hum Retroviruses       Date:  2011-09-21       Impact factor: 2.205

Review 4.  Oximes and Hydrazones in Bioconjugation: Mechanism and Catalysis.

Authors:  Dominik K Kölmel; Eric T Kool
Journal:  Chem Rev       Date:  2017-06-22       Impact factor: 60.622

5.  Oxime-based linker libraries as a general approach for the rapid generation and screening of multidentate inhibitors.

Authors:  Medhanit Bahta; Fa Liu; Sung-Eun Kim; Andrew G Stephen; Robert J Fisher; Terrence R Burke
Journal:  Nat Protoc       Date:  2012-03-15       Impact factor: 13.491

6.  Elucidation of New Binding Interactions with the Tumor Susceptibility Gene 101 (Tsg101) Protein Using Modified HIV-1 Gag-p6 Derived Peptide Ligands.

Authors:  Sung-Eun Kim; Fa Liu; Young Jun Im; Andrew G Stephen; Matthew J Fivash; Abdul A Waheed; Eric O Freed; Robert J Fisher; James H Hurley; Terrence R Burke
Journal:  ACS Med Chem Lett       Date:  2011-05-12       Impact factor: 4.345

7.  2-Bromo-N'-[(2Z)-butan-2-yl-idene]-5-methoxy-benzohydrazide.

Authors:  Jerry P Jasinski; Ray J Butcher; L P Suchitra; H S Yathirajan; B Narayana
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2009-10-31

8.  2-(4-Chloro-phen-oxy)acetohydrazide.

Authors:  Grzegorz Dutkiewicz; C S Chidan Kumar; B Narayana; H S Yathirajan; Maciej Kubicki
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2009-11-25

9.  (E)-2-(4-Chloro-phen-oxy)-N'-(pyridin-4-yl-methyl-idene)acetohydrazide.

Authors:  Xiao-Jin Rao; Wen-Shi Wu; Chuan-Hui Li; Yu-Min Huang
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2012-12-08

10.  Molecular characterization of feline immunodeficiency virus budding.

Authors:  Benjamin G Luttge; Miranda Shehu-Xhilaga; Dimiter G Demirov; Catherine S Adamson; Ferri Soheilian; Kunio Nagashima; Andrew G Stephen; Robert J Fisher; Eric O Freed
Journal:  J Virol       Date:  2007-12-19       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.